161 related articles for article (PubMed ID: 37116587)
1. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease.
Wang MX; Peng ZG
Pharmacol Ther; 2023 Jun; 246():108428. PubMed ID: 37116587
[TBL] [Abstract][Full Text] [Related]
2. Role of HSD17B13 in the liver physiology and pathophysiology.
Su W; Mao Z; Liu Y; Zhang X; Zhang W; Gustafsson JA; Guan Y
Mol Cell Endocrinol; 2019 Jun; 489():119-125. PubMed ID: 30365983
[TBL] [Abstract][Full Text] [Related]
3. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
5. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.
Zhang X; Wang Y; Liu P
Protein Cell; 2017 Jan; 8(1):4-13. PubMed ID: 27757845
[TBL] [Abstract][Full Text] [Related]
6. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
7. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
8. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.
Su W; Wang Y; Jia X; Wu W; Li L; Tian X; Li S; Wang C; Xu H; Cao J; Han Q; Xu S; Chen Y; Zhong Y; Zhang X; Liu P; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11437-42. PubMed ID: 25028495
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in 17beta-hydroxysteroid dehydrogenases.
Prehn C; Möller G; Adamski J
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):72-7. PubMed ID: 19444936
[TBL] [Abstract][Full Text] [Related]
12. Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice.
Adam M; Heikelä H; Sobolewski C; Portius D; Mäki-Jouppila J; Mehmood A; Adhikari P; Esposito I; Elo LL; Zhang FP; Ruohonen ST; Strauss L; Foti M; Poutanen M
FASEB J; 2018 Jun; 32(6):3434-3447. PubMed ID: 29401633
[TBL] [Abstract][Full Text] [Related]
13. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
14. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
[TBL] [Abstract][Full Text] [Related]
15. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
[TBL] [Abstract][Full Text] [Related]
16. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
18. 17B-hydroxysteroid dehydrogenases as acyl thioester metabolizing enzymes.
Hiltunen JK; Kastaniotis AJ; Autio KJ; Jiang G; Chen Z; Glumoff T
Mol Cell Endocrinol; 2019 Jun; 489():107-118. PubMed ID: 30508570
[TBL] [Abstract][Full Text] [Related]
19. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Ma Y; Brown PM; Lin DD; Ma J; Feng D; Belyaeva OV; Podszun MC; Roszik J; Allen JN; Umarova R; Kleiner DE; Kedishvili NY; Gavrilova O; Gao B; Rotman Y
Hepatology; 2021 May; 73(5):1701-1716. PubMed ID: 32779242
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
